Mnpa
Mnpa Brand names, Mnpa Analogs
Mnpa Brand Names Mixture
- No information avaliable
Mnpa Chemical_Formula
C4H6CaO4
Mnpa RX_link
No information avaliable
Mnpa fda sheet
Mnpa msds (material safety sheet)
Mnpa Synthesis Reference
No information avaliable
Mnpa Molecular Weight
158.17 g/mol
Mnpa Melting Point
> 160 oC
Mnpa H2O Solubility
No information avaliable
Mnpa State
Solid
Mnpa LogP
No information avaliable
Mnpa Dosage Forms
Capsule; Drops; Liquid; Powder for solution; Solution; Tablet
Mnpa Indication
Used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
Mnpa Pharmacology
Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Mnpa Absorption
40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Mnpa side effects and Toxicity
Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Mnpa Patient Information
No information avaliable
Mnpa Organisms Affected
Humans and other mammals
